A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Authors:
Open Access
- 15 November 2022
- journal article
- abstracts
- Published by American Society of Hematology in Blood
- Vol. 140 (Supplement) , 4405-4406